Devonian Health Group (CVE:GSD) Stock Price Down 16.6% – Here’s What Happened

Devonian Health Group Inc. (CVE:GSD)’s share price was down 16.6% during mid-day trading on Monday . The company traded as low as C$10.01 and last traded at C$10.01. Approximately 200 shares changed hands during trading, a decline of 84% from the average daily volume of 1,237 shares. The stock had previously closed at C$12.00.

Devonian Health Group Trading Down 16.6%

The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The business’s 50 day moving average price is C$12.34 and its 200-day moving average price is C$11.76. The firm has a market capitalization of C$27.84 million, a price-to-earnings ratio of -2.88 and a beta of 1.25.

About Devonian Health Group

Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.